<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83255">
  <stage>Registered</stage>
  <submitdate>9/10/2008</submitdate>
  <approvaldate>17/04/2009</approvaldate>
  <actrnumber>ACTRN12609000185268</actrnumber>
  <trial_identification>
    <studytitle>LBH589 in combination with External Beam Radiotherapy or Chemoradiation for Locally Advanced Non Small Cell Lung Cancer</studytitle>
    <scientifictitle>A dose finding study of oral LBH589 with radiation with or without chemotherapy for Stage III Non Small Cell Lung Cancer</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Lung cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intervention group 1:
LBH589, an oral histone deacetylase inhibitor, will be combined with radiation for treatment of stage III non small cell lung cancer (NSCLC) in 3 increasing dose levels- 20 mg, 30 mg and 45 mg. The drug is administered orally. The radiation will be delivered to a total dose of 40 Gy in 2 Gy per fraction. 3 patients will start treatment with 20 mg LBH589 and radiation and observed for dose limiting toxicities. In case of no or minimal toxicities the next 3 patients will be treated at second dose level i.e. 30 mg. The next and final dose level will be 45 mg. A patient will be treated at only one particular dose level. The treatment will last for the duration of radiation, i.e. 4 weeks. 
Intervention group 2:
Patients with stage III NSCLC will be treated with chemoradiation plus LBH589 in three increasing dose levels 20 mg, 30 mg and 45 mg. The total treatment duration will be 6 weeks. Radiation will be given at the dose of 60 Gy- 2 Gy per fraction. The chemotherapy will be intravenous cisplatin (50mg/m2 Days 1, 8 every 3 weeks) plus oral vinorelbine (50mg/m2 Days 1, 8 every 3 weeks) for 2 cycles. The first 3 patients will start treatment at 20 mg LBH589 with chemoradiation and observed for dose limiting toxicities. In case of no or minimal toxicities, the next three patients will be treated at 30 mg dose level. The final dose level will be 45 mg. The dose of chemotherapy and raditaion will remain constant throughout. A patient will be treated at only one dose level of LBH589 whether they experience any toxicity or not.</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>dose limiting toxicity and maximum tolerated dose using classical Fibonacci's phase I trial design.</outcome>
      <timepoint>The patients will be assessed for toxicities twice a week during treatment. Final assessment will be at week 4 after last treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>response rate using computerised tomography (CT) scan</outcome>
      <timepoint>4 weeks after completion of radiation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histological or cytological diagnosis of locally advanced (stage III) NSCLC
Adequate organ function
Performance score &lt; 2
Adequate lung functions with forced expiratory volume (FEV1) &gt; 1 L</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Concurrent treatment with other histone deacetylase inhibitors such as sodium valproate
Concurrent treatment with anti-arrythmics with a tendency to prolong QTc interval.
Patients on other investigational drugs within last 30 days
Pregnant or lactating females 
Patients who have any severe and/or uncontrolled medical conditions
Malabsorption syndrome</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/08/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Adelaide Hospital</primarysponsorname>
    <primarysponsoraddress>North Terrace
Adelaide, SA 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novartis Pharmaceuticals Australia Pty Limited</fundingname>
      <fundingaddress>54 Waterloo Road
North Ryde NSW 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will find the right amount of dose of a new oral drug called LBH589 in combination with radiation or chemoradiation for locally advanced lung cancer.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Nimit Singhal</name>
      <address>Royal Adelaide Hospital
North Terrace
Adelaide, SA 5000</address>
      <phone>+61 8 882224398</phone>
      <fax>+61 8 882224358</fax>
      <email>nimit.singhal@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Nimit Singhal</name>
      <address>Royal Adelaide Hospital
North Terrace
Adelaide, SA 5000</address>
      <phone>+61 8 882224398</phone>
      <fax>+61 8 882224358</fax>
      <email>nimit.singhal@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Nimit Singhal</name>
      <address>Royal Adelaide Hospital
North Terrace
Adelaide, SA 5000</address>
      <phone />
      <fax />
      <email />
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>